Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.266 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5868 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5303 | 0.36 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.5868 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5868 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.266 | 0.266 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5868 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.266 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.5868 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.266 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5303 | 0.5303 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.5868 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.266 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.266 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.5868 | 0.5868 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5868 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.5868 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.266 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.266 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.266 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0891 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.2589 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.9953 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 9.2 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.